Abstract
Background Targeting modifiable risk factors may have a role in the prevention of Alzheimer’s disease. However, the mechanisms by which these risk factors influence Alzheimer’s risk remain incompletely understood. Genomic structural equation modelling can reveal patterns of shared genetic architecture that provide insight into the pathophysiology of complex traits.
Methods We identified genome-wide association studies for Alzheimer’s disease and its major modifiable risk factors: less education, hearing loss, hypertension, high alcohol intake, obesity, smoking, depression, social isolation, physical inactivity, type 2 diabetes, sleep disturbance and socioeconomic deprivation. We performed linkage disequilibrium score regression among these traits, followed by exploratory factor analysis, confirmatory factor analysis and structural equation modelling.
Results We identified complex networks of linkage disequilibrium among Alzheimer’s disease risk factors. The data were best explained by a bi-factor model, incorporating a Common Factor for Alzheimer’s risk, and three orthogonal sub-clusters of risk factors, which were validated across the two halves of the autosome. The first sub-cluster was characterised by risk factors related to sedentary lifestyle behaviours, the second by traits associated with reduced life expectancy and the third by traits that are possible prodromes of Alzheimer’s disease. Alzheimer’s disease was more genetically distinct and displayed minimal shared genetic architecture with its risk factors, which was robust to the exclusion of APOE.
Conclusion Shared genetic architecture may contribute to epidemiological associations between Alzheimer’s disease and its risk factors. Understanding the biology reflected by this communality may provide novel mechanistic insights that could help to prioritise targets for dementia prevention.
Competing Interest Statement
IFF is funded by the George Henry Woolfe Legacy Fund (WOL1000B) provided by the Wolfson Institute of Preventive Medicine (Queen Mary University of London). CRM is funded by a grant from Barts Charity (MGU0366) and receives personal fees from GE Healthcare, outside the current study. RD reports personal fees from Biogen Idec, Merck, Celgene, Janssen, Novartis, and Genzyme outside of the current study. AJN reports personal fees from Britannia Pharmaceuticals, Profile, Neurology Academy, Roche, Biogen, LEK consulting, AbbVie, BIAL, and the Movement Disorders Society, outside of the current study. The other authors declare no competing interests.
Funding Statement
The research reported in this manuscript was supported by the George Henry Woolfe Legacy Fund (WOL1000B) provided to IFF by the Wolfson Institute of Preventive Medicine (Queen Mary University of London) and a grant received by CRM from Barts Charity (MGU0366).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We used publicly available GWAS summary statistics for this work (for individual links please refer to the Key Resources Table within the manuscript). As these datasets are summary statistics and de-identified no IRB oversight was necessary for the current study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data used in the study are all publicly available for download (GWAS summary statistics, LD scores and weights, and the reference genome file). See the Key Resources Table in the main manuscript for details.
http://web.pasteur-lille.fr/en/recherche/u744/igap/igap_download.php
https://www.med.unc.edu/pgc/download-results/mdd/
https://ctg.cncr.nl/software/summary_statistics
http://diagram-consortium.org/downloads.html
http://www.nealelab.is/uk-biobank
https://alkesgroup.broadinstitute.org/LDSCORE/
https://utexas.app.box.com/s/vkd36n197m8klbaio3yzoxsee6sxo11v
